Discover the World’s Fastest Business Insights
Get real-time alerts on funding rounds, executive hires, acquisitions, and more— plus verified contact details and AI-powered outreach to connect faster.
Sign up now to unlock exclusive data and opportunities.
Day One Announces $130 Million Series B Financing to Accelerate New Targeted Cancer Treatments for Children
Day One Announces $130 Million Series B Financing to Accelerate New Targeted Cancer Treatments for Children
Company Info
Company news
Fri, 17 Nov 2023 08:00:00 GMT
The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial - Nature.com
Tue, 11 May 2021 07:00:00 GMT
Day One Announces First Patient Dosed in FIREFLY-1 Pivotal Phase 2 Clinical Trial of DAY101 in Pediatric Progressive Low-Grade Glioma - Business Wire
Mon, 30 Oct 2023 07:00:00 GMT
FDA Accepts NDA for Tovorafenib in Pediatric Low-Grade Glioma - Targeted Oncology
Tue, 23 Feb 2021 08:00:00 GMT
Day One Expands Clinical-Stage Oncology Pipeline; Announces Global License Agreement with Merck KGaA, Darmstadt, Germany to Develop and Commercialize MEK Inhibitor Pimasertib - Business Wire
Never Miss an Opportunity: Your #1 Sales Intelligence Tool
Get lightning-fast updates on funding rounds, executive hires, contract awards, and more—powered by AI-driven insights to help you connect with the right prospects first.